Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2551
Invesco Financial Preferred ETF
PGF
$603M
| $976K | ﹤0.01% |
+54,500
| New | +$970K |
2020 Q2
0 quarters
|
|
|
ALNA
2552
DELISTED
Allena Pharmaceuticals
ALNA
| $975K | ﹤0.01% |
617,270
+215,492
| +54% | +$362K |
2019 Q1
5 quarters
|
|
2553
Horace Mann Educators
HMN
$1.85B
| $970K | ﹤0.01% |
26,400
-102,400
| -80% | -$3.6M |
2018 Q3
7 quarters
|
|
2554
Boston Scientific
BSX
$61.9B
| $969K | ﹤0.01% |
+27,605
| New | +$994K |
2020 Q2
0 quarters
|
|
2555
Vanguard Mortgage-Backed Securities ETF
VMBS
$15.4B
| $968K | ﹤0.01% |
+17,800
| New | +$969K |
2020 Q2
0 quarters
|
|
2556
Niagen Bioscience
NAGE
$213M
| $965K | ﹤0.01% |
+210,200
| New | +$941K |
2020 Q2
0 quarters
|
|
2557
Ascent Industries
ACNT
$122M
| $960K | ﹤0.01% |
128,300
-26,300
| -17% | -$228K |
2014 Q4
22 quarters
|
|
2558
Aterian
ATER
$11M
| $960K | ﹤0.01% |
+14,575
| New | +$704K |
2020 Q2
0 quarters
|
|
2559
RCM Technologies
RCMT
$294M
| $960K | ﹤0.01% |
716,218
+25,800
| +4% | +$36.6K |
2013 Q2
28 quarters
|
|
|
NXGN
2560
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $960K | ﹤0.01% |
87,476
-5,400
| -6% | -$56K |
2020 Q1
1 quarter
|
|
2561
X4 Pharmaceuticals
XFOR
$289M
| $959K | ﹤0.01% |
3,428
+1,633
| +91% | +$447K |
2019 Q4
2 quarters
|
|
2562
Red Violet
RDVT
$1.28B
| $953K | ﹤0.01% |
54,000
+28,500
| +112% | +$533K |
2018 Q4
6 quarters
|
|
2563
The Gap Inc
GAP
$8.16B
| $953K | ﹤0.01% |
75,500
-151,155
| -67% | -$1.36M |
2019 Q3
3 quarters
|
|
|
IMBI
2564
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
| $950K | ﹤0.01% |
271,328
+21,323
| +9% | +$55.4K |
2014 Q4
22 quarters
|
|
|
CNST
2565
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $950K | ﹤0.01% |
+31,600
| New | +$1.14M |
2020 Q2
0 quarters
|
|
2566
DELISTED
Superior Industries International
SUP
| $948K | ﹤0.01% |
557,909
+142,000
| +34% | +$203K |
2019 Q4
2 quarters
|
|
2567
Forward Industries Inc
FWDI
$560M
| $947K | ﹤0.01% |
72,871
+5,083
| +7% | +$59.6K |
2013 Q2
28 quarters
|
|
2568
Vanguard Russell 1000 Growth ETF
VONG
$47.9B
| $947K | ﹤0.01% |
19,200
+9,200
| +92% | +$417K |
2019 Q4
2 quarters
|
|
2569
iShares US Technology ETF
IYW
$27B
| $944K | ﹤0.01% |
+14,000
| New | +$845K |
2020 Q2
0 quarters
|
|
2570
Akso Health Group
AHG
$1.07B
| $941K | ﹤0.01% |
388,519
+31,800
| +9% | +$56.1K |
2018 Q3
7 quarters
|
|
2571
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
| $938K | ﹤0.01% |
82,068
-5,332
| -6% | -$63.4K |
2020 Q1
1 quarter
|
|
|
RUBY
2572
DELISTED
Rubius Therapeutics, Inc
RUBY
| $930K | ﹤0.01% |
+155,500
| New | +$918K |
2020 Q2
0 quarters
|
|
2573
Brookfield Infrastructure
BIPC
$4.6B
| $926K | ﹤0.01% |
+30,489
| New | +$885K |
2020 Q2
0 quarters
|
|
2574
iShares MSCI Mexico ETF
EWW
$1.5B
| $925K | ﹤0.01% |
29,000
-33,300
| -53% | -$1.01M |
2020 Q1
1 quarter
|
|
2575
VanEck Oil Services ETF
OIH
$1.87B
| $925K | ﹤0.01% |
7,590
-1,905
| -20% | -$213K |
2018 Q2
8 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.